BGI Suspends Clinical NGS-based Trisomy Testing in China | GenomeWeb

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

NEW YORK (GenomeWeb News) – BGI said this week that it is working with its collaborators to suspend the clinical application of its non-invasive fetal trisomy test in mainland China following a recent announcement from Chinese officials that genetic tests should be regulated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.